HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SNY
Sanofi
SNY's fundamentals are mixed: it turned 24% of its revenue into free cash flow, but its operating margin fell 4 points to 15%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SNY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
SNY's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $5.73 | -88% |
| Fair | 19x | $10.07 | -79% |
| Expensive | 31x | $16.50 | -66% |
| Current | 89x | $48.46 | — |
Historical ranges are pointers, not guarantees.
SNY's PE is 89x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SNY Forward outlook
There aren't enough analyst estimates for SNY to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.54 | -87% |
| Q1 2026 | $2.17 | -27% |
| Q4 2025 | $2.27 | -15% |
| Q3 2025 | $4.28 | +112% |
| Q2 2025 | $4.27 | +127% |
| Q1 2025 | $2.99 | +49% |
| Q4 2024 | $2.66 | +11% |
| Q3 2024 | $2.02 | -50% |
SNY has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SNY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.7B | +15% |
| Q1 2026 | $12.5B | +6% |
| Q4 2025 | $13.6B | +60% |
| Q3 2025 | $14.6B | -7% |
| Q2 2025 | $11.9B | -5.7% |
| Q1 2025 | $11.8B | +9% |
| Q4 2024 | $8.5B | -37% |
| Q3 2024 | $15.7B | +11% |
SNY's revenue has picked up after three years of holding roughly level: $13.7B last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 19% | +5.6 points |
| Q1 2026 | 20% | -0.9 points |
| Q4 2025 | -8.5% | -16 points |
| Q3 2025 | 28% | +1.8 points |
| Q2 2025 | 14% | -0.3 points |
| Q1 2025 | 21% | +8.3 points |
| Q4 2024 | 7.5% | +4.7 points |
| Q3 2024 | 26% | +0.4 points |
SNY has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SNY on cash flow, with more consistent year-over-year improvement.
SNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.3B | +$4.3B |
| Q1 2026 | $1.9B | -20% |
| Q4 2025 | $1.8B | +$1.8B |
| Q3 2025 | $5.1B | +$5.1B |
| Q2 2025 | $0 | +$458.7M |
| Q1 2025 | $2.3B | +$2.3B |
| Q4 2024 | $0 | -100% |
| Q3 2024 | $0 | $0 |
SNY generated $13.1B in free cash flow over the past year, about six times what it generated the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SNY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -15.2M shares |
| 1 year | -3% | -74.6M shares |
| 3 years | -4.3% | -108M shares |
| 5 years | -4.4% | -111M shares |
| Available history | -4.4% | -111M shares |
SNY has 2.4B diluted shares, down 3% from a year ago, with $1.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1.3B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $32.2M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SNY spent $1.3B buying back its own shares over the past year, after none the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over SNY on leverage, with a lower net debt burden relative to earnings.
SNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.0x | Healthy |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.0x | Very low |
| Q2 2024 | 2.1x | Moderate |
SNY's net debt is about 1.2 years of its operating earnings (EBITDA), up from less than a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.1 | Neutral |
| Stochastic | 86.8 | Overbought |
SNY's weekly RSI is 64 (neutral) and its Stochastic is 87 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SNY PE vs Healthcare Sector
| Metric | SNY | Sector median | Relative |
|---|---|---|---|
| PE | 89x | 26x | 244% above |
| PE % | 100 | 29 | 71 pts above |
SNY is trading at 89x earnings, a 244% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $42.9 | 13% above |
| 20 week MA | $43.4 | 12% above |
| 50 week MA | $45.1 | 7.5% above |
| 100 week MA | $47.9 | 1.1% above |
| 200 week MA | $49.4 | 1.9% below |
SNY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.9 | $47.5 | -6.7% |
| 2021 | $47.5 | $49.8 | +5% |
| 2022 | $49.8 | $48.5 | -2.6% |
| 2023 | $48.5 | $49.7 | +2.5% |
| 2024 | $49.7 | $48.7 | -2% |
| 2025 | $48.7 | $48.5 | -0.5% |
| 2026 YTD | $48.5 | $48.5 | 0% |
SNY has the edge over HIMS on returns for 2026, with the stronger performance.